Saadvik Raghuram Y, Head of Department of Medical Oncology at Arete Hospitals, shared a post on X:
“Now a randomized trial of Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations
-
Exclusions: T790M; Exon 20 insertions
-
mPFS 10.6 vs 5.7 mo favoring AFATINIB
-
ORR 62% vs 56% favouring AFATINIB.”
More posts featuring Saadvik Raghuram Y.